The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Therapeutics Targeting FGF Signaling Network in Human Diseases
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
FGF23 induces left ventricular hypertrophy
Faul, C., Amaral, A. P., Oskouei, B., Hu, M.-C., Sloan, A., Isakova, T., Gutiérrez, O. M., Aguillon-Prada, R., Lincoln, J., Hare, J. M., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci46122 · Cited by 2,027
PD-1 and PD-1 ligands: from discovery to clinical application
Okazaki, T., & Honjo, T. (2007) · International Immunology · doi:10.1093/intimm/dxm057 · Cited by 1,310
The genetic architecture of type 2 diabetes
Fuchsberger, C., Flannick, J., Teslovich, T. M., Mahajan, A., Agarwala, V., Gaulton, K. J., Ma, C., Fontanillas, P., Moutsianas, L., McCarthy, D. J., et al. (2016) · Nature · doi:10.1038/nature18642 · Cited by 1,051
Acquired resistance to TKIs in solid tumours: learning from lung cancer
Camidge, D. R., Pao, W., & Sequist, L. V. (2014) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2014.104 · Cited by 862 · cited 1×
“Directly targeted therapies are available for patients with actionablemutations and/or alterations in the genes encoding RTKs, such as ALK fusion [81,82], EGFR mutation [83,84], FGFR1 amplification [36], and FLT3 internal tandem duplication (ITD) [85,86] (Figure 3A).”
BackgroundTherapeutic potential of the endocrine fibroblast growth factors FGF19, FGF21 and FGF23
Degirolamo, C., Sabbà, C., & Moschetta, A. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2015.9 · Cited by 424 · cited 4×
“FGF21 (LY2405319) [9_TD$DIFF] GF21 [14_TD$DIFF] receptor T2DM P1 (NCT01869959) [57]”
BackgroundInfluentialChen, P.-Y., Qin, L., Barnes, C., Charisse, K., Yi, T., Zhang, X., Ali, R., Medina, P. P., Yu, J., Slack, F. J., et al. (2012) · Cell Reports · doi:10.1016/j.celrep.2012.10.021 · Cited by 304
Costa, D. B. (2016) · Translational Lung Cancer Research · doi:10.21037/tlcr.2016.06.04 · Cited by 71
Maher, G. J., McGowan, S. J., Giannoulatou, E., Verrill, C., Goriely, A., & Wilkie, A. O. M. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1521325113 · Cited by 59
Cited by
FGF/FGFR signaling in health and disease
Xie, Y., Su, N., Yang, J., Tan, Q., Huang, S., Jin, M., Ni, Z., Zhang, B., Zhang, D., Luo, F., et al. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00222-7 · Cited by 904
Targeting fibrosis: mechanisms and clinical trials
Zhao, M., Wang, L., Wang, M., Zhou, S., Lu, Y., Cui, H., Racanelli, A. C., Zhang, L., Ye, T., Ding, B., et al. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01070-3 · Cited by 547
Katoh, M. (2017) · International Journal of Oncology · doi:10.3892/ijo.2017.4129 · Cited by 465
Self-citationFibroblast growth factor receptors as treatment targets in clinical oncology
Katoh, M. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0115-y · Cited by 352
Self-citationThe Role of Fibroblast Growth Factor (FGF) Signaling in Tissue Repair and Regeneration
Farooq, M., Khan, A. W., Kim, M. S., & Choi, S. (2021) · Cells · doi:10.3390/cells10113242 · Cited by 346
Metadata
- Authors
- Katoh, M.
- Venue
- Trends in Pharmacological Sciences
- Publisher
- Elsevier BV
- Published
- 2016-12
- Volume
- 37
- Issue
- 12
- Pages
- 1081-1096
- ISSN
- 0165-6147 (ISSN-L)
- OpenAlex
- W2541714644
- Cited by
- 204
- References
- 8
- FWCI
- 1.48
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.